SHOW

Earlier this year a GOED-sponsored meta-analysis linking EPA/DHA Omega-3s to a reduced risk of coronary heart disease (CHD) was published in the Mayo Clinic Proceedings.The study looked specifically at CHD, which is a major contributor to cardiovascular deaths. Both randomized controlled trials (RCTs) and prospective cohort trials were included.Among RCTs, there was a no statistically significant reduction in CHD risk with EPA+DHAprovision with subgroup analyses revealing a statisticallysignificant CHD risk reduction with EPA+DHA provision among higher-risk populations, includingparticipants with elevated triglyceride levels (16%) and elevated LDL cholesterol (14%). Meta-analysis of data from prospective cohortstudies revealed an 18% risk reduction.